$SYRE
Spyre Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022021529 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $168.0K $174.0K $1.399M
YoY Change -95.39% -87.56%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.079M $6.952M $6.839M
YoY Change -30.46% 1.65% 20.62%
% of Gross Profit
Research & Development $14.25M $11.98M $14.85M
YoY Change -15.08% -19.36% 19.3%
% of Gross Profit
Depreciation & Amortization $385.0K $401.0K $412.0K
YoY Change -6.33% -2.67% 64.8%
% of Gross Profit
Operating Expenses $19.33M $18.93M $21.69M
YoY Change -19.75% -12.74% 19.71%
Operating Profit -$18.76M -$20.29M
YoY Change -7.58% 11.97%
Interest Expense $410.0K $288.0K $36.00K
YoY Change 1105.88% 700.0% -60.0%
% of Operating Profit
Other Income/Expense, Net -$32.00K $312.0K -$24.00K
YoY Change 113.33% -1400.0%
Pretax Income -$18.78M -$18.44M -$20.28M
YoY Change -8.03% -9.06% 12.48%
Income Tax $38.00K -$209.0K $26.00K
% Of Pretax Income
Net Earnings -$18.82M -$18.23M -$20.31M
YoY Change -7.94% -10.21% 12.61%
Net Earnings / Revenue -11203.57% -10479.31% -1451.54%
Basic Earnings Per Share -$0.19 -$0.31
Diluted Earnings Per Share -$0.20 -$0.19 -$308.7K
COMMON SHARES
Basic Shares Outstanding 61.51M 61.17M 65.79M
Diluted Shares Outstanding 94.20M 65.79M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $55.71M $73.68M $114.3M
YoY Change -40.18% -35.52% -19.23%
Cash & Equivalents $34.86M $38.99M $26.50M
Short-Term Investments $20.85M $34.69M $87.76M
Other Short-Term Assets $6.172M $7.874M $5.086M
YoY Change 24.74% 54.82% 15.59%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $62.26M $82.22M $117.5M
YoY Change -37.04% -30.03% -18.62%
LONG-TERM ASSETS
Property, Plant & Equipment $3.220M $3.555M $8.813M
YoY Change -29.22% -59.66% 68.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $683.0K $749.0K $2.734M
YoY Change -18.88% -72.6% 2140.98%
Total Long-Term Assets $8.886M $9.347M $11.55M
YoY Change -19.47% -19.05% 2.8%
TOTAL ASSETS
Total Short-Term Assets $62.26M $82.22M $117.5M
Total Long-Term Assets $8.886M $9.347M $11.55M
Total Assets $71.14M $91.57M $129.1M
YoY Change -35.28% -29.05% -17.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $677.0K $4.178M $1.863M
YoY Change -79.6% 124.26% -18.82%
Accrued Expenses $13.45M $13.00M $13.77M
YoY Change -4.29% -5.66% 13.83%
Deferred Revenue $2.696M $2.679M $6.405M
YoY Change -24.61% -58.17%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $16.00K
YoY Change -96.17%
Total Short-Term Liabilities $14.66M $17.68M $20.43M
YoY Change -27.24% -13.46% 42.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $0.00 $6.552M
YoY Change -100.0% -100.0% 31.04%
Total Long-Term Liabilities $0.00 $0.00 $6.552M
YoY Change -100.0% -100.0% 31.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.66M $17.68M $20.43M
Total Long-Term Liabilities $0.00 $0.00 $6.552M
Total Liabilities $20.84M $24.01M $26.98M
YoY Change -19.8% -11.0% 39.07%
SHAREHOLDERS EQUITY
Retained Earnings -$425.6M -$406.8M -$321.4M
YoY Change 24.51% 26.57% 26.89%
Common Stock $476.0M $474.5M
YoY Change 11.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $50.31M $67.56M $102.1M
YoY Change
Total Liabilities & Shareholders Equity $71.14M $91.57M $129.1M
YoY Change -35.28% -29.05% -17.06%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$18.82M -$18.23M -$20.31M
YoY Change -7.94% -10.21% 12.61%
Depreciation, Depletion And Amortization $385.0K $401.0K $412.0K
YoY Change -6.33% -2.67% 64.8%
Cash From Operating Activities -$18.14M -$15.07M -$17.00M
YoY Change -5.85% -11.36% -3.02%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$1.000K -$93.00K
YoY Change -98.92% -83.68%
Acquisitions
YoY Change
Other Investing Activities $14.00M $16.50M $5.870M
YoY Change 44.88% 181.09% -7.56%
Cash From Investing Activities $14.00M $16.50M $5.777M
YoY Change 44.88% 185.6% -0.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -8.000K -130.0K 1.143M
YoY Change -110.0% -111.37% 357.2%
NET CHANGE
Cash From Operating Activities -18.14M -15.07M -17.00M
Cash From Investing Activities 14.00M 16.50M 5.777M
Cash From Financing Activities -8.000K -130.0K 1.143M
Net Change In Cash -4.148M 1.301M -10.08M
YoY Change -56.45% -112.91% -12.27%
FREE CASH FLOW
Cash From Operating Activities -$18.14M -$15.07M -$17.00M
Capital Expenditures $0.00 -$1.000K -$93.00K
Free Cash Flow -$18.14M -$15.07M -$16.91M
YoY Change -5.85% -10.88% -0.31%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001636282
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37722
dei Entity Registrant Name
EntityRegistrantName
AEGLEA BIOTHERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4312787
dei Entity Address Address Line1
EntityAddressAddressLine1
805 Las Cimas Parkway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78746
dei City Area Code
CityAreaCode
512
dei Local Phone Number
LocalPhoneNumber
942-2935
dei Trading Symbol
TradingSymbol
AGLE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
us-gaap Operating Income Loss
OperatingIncomeLoss
-45207000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-18000
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value Per Share
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1529000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1838000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7874000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4948000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2161000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
82219000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
98891000
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
61511078
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38989000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15142000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
34687000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
77986000
CY2022Q3 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
669000
CY2021Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
815000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3555000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4549000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3514000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3806000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
749000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
842000
CY2022Q3 us-gaap Assets
Assets
91566000
CY2021Q4 us-gaap Assets
Assets
109926000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4178000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3319000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
587000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
436000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
505000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2359000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12408000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14030000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17678000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20144000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4159000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4608000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2174000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1217000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
16000
CY2022Q3 us-gaap Liabilities
Liabilities
24011000
CY2021Q4 us-gaap Liabilities
Liabilities
25985000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-4000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61511078
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61511078
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49355130
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49355130
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
474535000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
425765000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-184000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-406802000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-341809000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
67555000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
83941000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91566000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
109926000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
174000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1399000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15095000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11977000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14853000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44328000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40287000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6952000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6839000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23452000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20015000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
18929000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
21692000
us-gaap Operating Expenses
OperatingExpenses
67780000
us-gaap Operating Expenses
OperatingExpenses
60302000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18755000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20293000
us-gaap Operating Income Loss
OperatingIncomeLoss
-65619000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
288000
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
36000
us-gaap Investment Income Net
InvestmentIncomeNet
427000
us-gaap Investment Income Net
InvestmentIncomeNet
77000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-24000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-107000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
312000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
452000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18443000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20281000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-65167000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-45237000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-209000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-174000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
118000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18234000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20307000
us-gaap Net Income Loss
NetIncomeLoss
-64993000
us-gaap Net Income Loss
NetIncomeLoss
-45355000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94197958
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94197958
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65789449
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65789449
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80574683
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
80574683
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
65675915
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
65675915
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18234000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20307000
us-gaap Net Income Loss
NetIncomeLoss
-64993000
us-gaap Net Income Loss
NetIncomeLoss
-45355000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-38000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-10000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-87000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
74000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-77000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18198000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20316000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65157000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45364000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
83941000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
184000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2101000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-13000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-120000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24436000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
61657000
CY2022Q2 agle Stock Issued During Period Value Common Stock And Pre Funded Warrants Registered Direct Offering
StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering
42873000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2017000
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-36000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-31000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22323000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
84157000
CY2022Q3 agle Stock Issued During Period Value Common Stock Registered Direct Offering
StockIssuedDuringPeriodValueCommonStockRegisteredDirectOffering
-8000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
38000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1566000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-38000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
74000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18234000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
67555000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
139832000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
224000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
146000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1757000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
4000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18218000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
123755000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2080000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-6830000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
119024000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
230000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1036000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2107000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-10000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20307000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
102081000
us-gaap Profit Loss
ProfitLoss
-64993000
us-gaap Profit Loss
ProfitLoss
-45355000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1182000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1165000
us-gaap Share Based Compensation
ShareBasedCompensation
5684000
us-gaap Share Based Compensation
ShareBasedCompensation
5944000
agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
-351000
agle Payment For Discount Premium On Investments Net
PaymentForDiscountPremiumOnInvestmentsNet
374000
agle Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
292000
agle Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
334000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
175000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-490000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-2000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
859000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-390000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-146000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2863000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1555000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1293000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-828000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-897000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
6405000
agle Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-297000
agle Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-286000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62004000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34448000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
573000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
35000000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
119829000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
78046000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
88120000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43008000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32282000
agle Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
42874000
agle Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
222000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1654000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
410000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
341000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42686000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1313000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-152000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23538000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-65435000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16980000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
91937000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
40518000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26502000
agle Leased Assets Obtained In Exchange For Lease Obligations
LeasedAssetsObtainedInExchangeForLeaseObligations
0
agle Leased Assets Obtained In Exchange For Lease Obligations
LeasedAssetsObtainedInExchangeForLeaseObligations
872000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 agle Working Capital
WorkingCapital
64500000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-406800000
CY2022Q3 agle Cash Cash Equivalents Marketable Securities And Restricted Cash
CashCashEquivalentsMarketableSecuritiesAndRestrictedCash
75200000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
34687000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
77986000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
34687000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
77986000
CY2022Q2 agle Placement Agent Fees And Offering Costs
PlacementAgentFeesAndOfferingCosts
2100000
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
agle Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised
MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised
0.0499
agle Maximum Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised To Certain Holders
MaximumOwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders
0.0999
agle Period After Notice Received By Company Maximum Ownership Percentage To Be Effective Description
PeriodAfterNoticeReceivedByCompanyMaximumOwnershipPercentageToBeEffectiveDescription
The revised Maximum Ownership Percentage would be effective 61 days after the notice is received by the Company
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgements about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of our financial statements relate to accrued research and development costs, stock-based compensation expense and revenue recognition.</span></p>
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
26020000
CY2022Q3 agle Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
0
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
26020000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
34803000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
116000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
34687000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8888000
CY2021Q4 agle Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
0
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
8888000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
78024000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
41000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
77986000
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
35933000
CY2022Q3 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
116000
CY2022Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
35933000
CY2022Q3 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
116000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
59998000
CY2021Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
41000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
59998000
CY2021Q4 us-gaap Held To Maturity Securities Continuous Unrealized Loss Position Accumulated Loss
HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
41000
CY2022Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4690000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4988000
CY2022Q3 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
5842000
CY2021Q4 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
5995000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1514000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2264000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
362000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
783000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12408000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
14030000
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
17372312
CY2022Q2 agle Class Of Warrant Or Right Offering Price Of Warrants Or Rights
ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights
1.5999
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42900000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3576000
agle Contract With Customer Liability Revenue Recognized Including Additions
ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions
1264000
agle Contract With Customer Liability Deductions Through Contracts Acquired
ContractWithCustomerLiabilityDeductionsThroughContractsAcquired
2161000
CY2022Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2679000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2022Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2021Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0

Files In Submission

Name View Source Status
agle-20220930_cal.xml Edgar Link unprocessable
0000950170-22-021529-index-headers.html Edgar Link pending
0000950170-22-021529-index.html Edgar Link pending
0000950170-22-021529.txt Edgar Link pending
0000950170-22-021529-xbrl.zip Edgar Link pending
agle-20220930.htm Edgar Link pending
agle-20220930.xsd Edgar Link pending
agle-ex31_1.htm Edgar Link pending
agle-ex31_2.htm Edgar Link pending
agle-ex32_1.htm Edgar Link pending
agle-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
agle-20220930_def.xml Edgar Link unprocessable
agle-20220930_pre.xml Edgar Link unprocessable
agle-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
agle-20220930_htm.xml Edgar Link completed
img116064786_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending